Stockreport

Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS [Yahoo! Finance]

Oculis Holding AG - Ordinary shares  (OCS) 
PDF Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Doubl [Read more]